Literature DB >> 11843959

Immune response to a 26-kDa protein, alkyl hydroperoxide reductase, in Helicobacter pylori-infected Mongolian gerbil model.

J Yan1, T Kumagai, M Ohnishi, I Ueno, H Ota.   

Abstract

BACKGROUND: The host immune response is thought to play an important role in the outcome of Helicobacter pylori infection. The successful development of the H. pylori-infected Mongolian gerbil model that mimics human disease has enabled study of the antibody response against H. pylori antigens.
MATERIALS AND METHODS: Serum samples from ulcer and carcinogenesis models of H. pylori-infected gerbils were used to screen for H. pylori antigens that cause a humoral immune response in the infected hosts. H. pylori alkyl hydroperoxide reductase (AhpC) is one such antigen on which we report here. The tsaA gene encoding AhpC was amplified by PCR from H. pylori ATCC 43504 strain, cloned into pMAL(TM)-c2 expression vector and expressed in Escherichia coli. Maltose-binding protein fusion protein (MBP-AhpC) was purified by a MBP affinity column. Using purified recombinant AhpC protein as an antigen, the antibody response and changes of antibody levels against AhpC in the gerbil models were studied by Western blotting and ELISA.
RESULTS: Antibody against AhpC was negative in the early stages of infection, and became positive in the gerbils with the emergence of gastric diseases such as chronic active gastritis, gastric ulcer and gastric cancer. The antibody levels (ELISA) increased gradually over time and were higher in gerbils with gastric ulcer than that in gerbils without ulcers.
CONCLUSIONS: Use of the gerbil model that mimics human H. pylori infection is likely to provide insights into the role of H. pylori-specific antigens possibly related to the subsequent development of gastric diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11843959     DOI: 10.1046/j.1523-5378.2001.00038.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  6 in total

1.  Serum Helicobacter pylori KatA and AhpC antibodies as novel biomarkers for gastric cancer.

Authors:  Bing Zhang; Hai-Lin Li; Qing Fan; Fang Guo; Xi-Yun Ren; Hai-Bo Zhou; Ji-Wei Zhu; Ya-Shuang Zhao; Wen-Jing Tian
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

2.  B-cell and T-cell immune responses to experimental Helicobacter pylori infection in humans.

Authors:  Zhannat Z Nurgalieva; Margaret E Conner; Antone R Opekun; Carl Q Zheng; Susan N Elliott; Peter B Ernst; Michael Osato; Mary K Estes; David Y Graham
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

3.  Differential proteomic analysis of the Bacillus anthracis secretome: distinct plasmid and chromosome CO2-dependent cross talk mechanisms modulate extracellular proteolytic activities.

Authors:  Theodor Chitlaru; Orit Gat; Yael Gozlan; Naomi Ariel; Avigdor Shafferman
Journal:  J Bacteriol       Date:  2006-05       Impact factor: 3.490

4.  Relationship between Helicobacter pylori virulence factors and regulatory cytokines as predictors of clinical outcome.

Authors:  Carolina Serrano; Maria Ines Diaz; Alejandra Valdivia; Alex Godoy; Alfredo Peña; Antonio Rollan; Arturo Kirberg; Eduardo Hebel; Jaqueline Fierro; Gabriela Klapp; Alejandro Venegas; Paul R Harris
Journal:  Microbes Infect       Date:  2007-01-12       Impact factor: 2.700

5.  The antioxidant protein alkylhydroperoxide reductase of Helicobacter pylori switches from a peroxide reductase to a molecular chaperone function.

Authors:  Ming-Hong Chuang; Ming-Shiang Wu; Wan-Lin Lo; Jaw-Town Lin; Chi-Huey Wong; Shyh-Horng Chiou
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-15       Impact factor: 11.205

6.  Immune reactions against elongation factor 2 kinase: specific pathogenesis of gastric ulcer from Helicobacter pylori infection.

Authors:  Kiyoshi Ayada; Kenji Yokota; Yoshiro Kawahara; Yumiko Yamamoto; Kazuyuki Hirai; Tomoki Inaba; Masahide Kita; Hiroyuki Okada; Kazuhide Yamamoto; Keiji Oguma
Journal:  Clin Dev Immunol       Date:  2009-07-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.